Randomized, placebo controlled tial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 25, Issue 4, 1996, Pages 194-199

  Gotzsche P C ^a,h   Hansen, M ^a   Stoltenberg, M ^a   Svendsen, A ^b   Beier, J ^b   Faarvang, K L ^c   Wangel, M ^d   Rydgren, L ^e   Halberg, P ^a   Juncker, P ^b   Andersen, V ^c   Hansen, T Mørk ^f   Endahl, L ^g  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Sweden)

^d Gråsten Arthritis Hospital   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h Rigshospitalet   (Denmark)

Author keywords

Bias; Methotrexate; Observer variation; Penicillamine; Placebo; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

METHOTREXATE; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 9444275374     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749609069987     Document Type: Article

References (16)

1. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two meta-analyses. Arthritis Rheum 1990; 33: 1449-61.
2. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. J Clin Epidemiol 1992; 45: 587-94.
3. Felson DT, Anderson JJ. Critique of meta-analysis of second-line antirheumatic drugs [comment to the editors]. J Clin Epidemiol 1993; 46: 315-19.
4. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs [comment to the editors]. J Clin Epidemiol 1993; 46: 319-21.
5. Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 1983; 309: 1023-8.
6. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992; 263: 374-8.
7. Arnett FC, Edsworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The 1987 revised American Rheumatism Association criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
8. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
9. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4.
10. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA 1994; 272: 1926-31.
11. Williams JW, Holleman DR, Samsa GP, Simel DL. Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA 1995; 273: 1015-21.
12. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008-14.
13. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA 1975; 231: 1038-42.
14. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. Scand J Rheumatol 1993; 22: 255-60.
15. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 1990; 43: 1313-8.
16. Hansen TM, Keiding S, Lauritzen SL, Manthorpe R, Sørensen SF, Wiik A. Clinical assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 1979; 8: 101-5.